BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...good safety profiles in rats. Intranasal lipopeptide prevents SARS-CoV-2 transmission in ferretsA team led by Columbia University...
...Wales Aminex Therapeutics Inc. Rice University Daiichi Sankyo Co. Ltd. Chinese Academy of Sciences Sichuan University Merck & Co. Inc. Vertex Pharmaceuticals Inc. Columbia University Erasmus...
BioCentury | Jan 28, 2021
Product Development

Vulnerability of COVID-19 mAbs to emerging variants: Data Byte

...change when the virus mutates.A paper published Tuesday in bioRxiv by Columbia University...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...Institute (HHMI) Janelia Research campus; and Mukherjee chairs Myeloid Therapeutics Inc.’s SAB and serves as a Columbia University...
BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

...managing partner at 5AM Ventures, and Siddhartha Mukherjee, a cancer and stem cell biologist at Columbia University...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...and middle-income countries. Partners AbCellera Biologics Inc. Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) and Columbia University...
BioCentury | Aug 27, 2020
Distillery Therapeutics

siRNAs against plaque-destabilizing molecule CAMK2G for atherosclerosis

...as aboveemail: jshi@bwh.harvard.eduCONTACT: Ira Tabas, Columbia University Irving Medical Center, New York, N.Y.email: iat1@columbia.edu Claire Quang Harvard Medical School Columbia University Calcium...
BioCentury | Aug 18, 2020
Product Development

SalivaDirect slots into growing matrix of resource-saving COVID-19 tests

...RNA in saliva samples; the technology, developed at Columbia University...
BioCentury | May 28, 2020
Distillery Therapeutics

Increasing WWTR1 degradation for NASH

...X. et al. Cell Metab. ; published online May 5, 2020 doi:10.1016/j.cmet.2020.03.010 CONTACT: Xiaobo Wang, Columbia University...
...Center, New York, N.Y. email: xw2279@columbia.edu CONTACT: Ira Tabas, same affiliation as above email: iat1@columbia.edu Claire Quang Columbia University WW...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

...an administrative head of Epi4K and the director of the Institute for Genomic Medicine at Columbia University...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...hired Owen O’Connor as CSO. He was director of the Center for Lymphoid Malignancies at Columbia University...
Items per page:
1 - 10 of 518
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...good safety profiles in rats. Intranasal lipopeptide prevents SARS-CoV-2 transmission in ferretsA team led by Columbia University...
...Wales Aminex Therapeutics Inc. Rice University Daiichi Sankyo Co. Ltd. Chinese Academy of Sciences Sichuan University Merck & Co. Inc. Vertex Pharmaceuticals Inc. Columbia University Erasmus...
BioCentury | Jan 28, 2021
Product Development

Vulnerability of COVID-19 mAbs to emerging variants: Data Byte

...change when the virus mutates.A paper published Tuesday in bioRxiv by Columbia University...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...Institute (HHMI) Janelia Research campus; and Mukherjee chairs Myeloid Therapeutics Inc.’s SAB and serves as a Columbia University...
BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

...managing partner at 5AM Ventures, and Siddhartha Mukherjee, a cancer and stem cell biologist at Columbia University...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...and middle-income countries. Partners AbCellera Biologics Inc. Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) and Columbia University...
BioCentury | Aug 27, 2020
Distillery Therapeutics

siRNAs against plaque-destabilizing molecule CAMK2G for atherosclerosis

...as aboveemail: jshi@bwh.harvard.eduCONTACT: Ira Tabas, Columbia University Irving Medical Center, New York, N.Y.email: iat1@columbia.edu Claire Quang Harvard Medical School Columbia University Calcium...
BioCentury | Aug 18, 2020
Product Development

SalivaDirect slots into growing matrix of resource-saving COVID-19 tests

...RNA in saliva samples; the technology, developed at Columbia University...
BioCentury | May 28, 2020
Distillery Therapeutics

Increasing WWTR1 degradation for NASH

...X. et al. Cell Metab. ; published online May 5, 2020 doi:10.1016/j.cmet.2020.03.010 CONTACT: Xiaobo Wang, Columbia University...
...Center, New York, N.Y. email: xw2279@columbia.edu CONTACT: Ira Tabas, same affiliation as above email: iat1@columbia.edu Claire Quang Columbia University WW...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

...an administrative head of Epi4K and the director of the Institute for Genomic Medicine at Columbia University...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...hired Owen O’Connor as CSO. He was director of the Center for Lymphoid Malignancies at Columbia University...
Items per page:
1 - 10 of 518